MiRNAs Evaluate the Prognosis of Sepsis by Dynamic Study (METPSDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01459822
Recruitment Status : Unknown
Verified August 2011 by Chinese PLA General Hospital.
Recruitment status was:  Recruiting
First Posted : October 26, 2011
Last Update Posted : October 26, 2011
Information provided by:
Chinese PLA General Hospital

Brief Summary:
Sepsis is a common cause of death in intensive care unit, timely and accurate diagnosis and treatment directly affect the survival rate. MiRNA is a post-transcriptional small RNA which regulate mRNA expression. The present study was designed to observe the selected miRNA expression which evaluate the sepsis prognosis in the progression of sepsis in order to be a new target for the treatment of sepsis.

Condition or disease

Detailed Description:
The study is a non-intervention observational study. Purpose of this study is to observe some selected miRNA expression which evaluate the sepsis prognosis in the progression of sepsis . The investigators will collect serum samples from patients with sepsis in SICU, RICU and EICU on the 1st、3rd、5th、7th、10th、14th day of 301 Hospital since November 2011 , and then use mirVana PARIS kit extract total RNA and use qRT-PCR detect miRNAS expression in serum which can evaluate the prognosis of sepsis, and statistical analysis the miRNAS expression correlation with SOFA score.

Study Type : Observational
Estimated Enrollment : 70 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: MiRNAhs in the Evaluation of the Value of Sepsis Prognosis Dynamics Observational Research
Study Start Date : August 2011
Estimated Primary Completion Date : July 2013
Estimated Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis

Survival Group
Death Group

Primary Outcome Measures :
  1. all cause mortality [ Time Frame: 28days after admited in ICU ]

Biospecimen Retention:   Samples Without DNA
human serum

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
within 24 hours after admited in ICU

Inclusion Criteria:

  • Clinical diagnosis of sepsis
  • Patients who agree with the study

Exclusion Criteria:

  • Aged <18 years;
  • Into the group who died within 24 hours;
  • Agranulocytosis (<0.5 × 109 / L);
  • Combined HIV infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01459822

Contact: Jie Deng, master +86 18610095120

China, Haidian
Chinese PLA General Hospital Recruiting
Beijing, Haidian, China, 100853
Contact: China         
Sponsors and Collaborators
Chinese PLA General Hospital
Study Director: LiXin Xie, doctor Pneumology Department of chinese PLA General Hospital Identifier: NCT01459822     History of Changes
Other Study ID Numbers: 301PLAGH-20110824005
First Posted: October 26, 2011    Key Record Dates
Last Update Posted: October 26, 2011
Last Verified: August 2011

Keywords provided by Chinese PLA General Hospital:

Additional relevant MeSH terms:
Systemic Inflammatory Response Syndrome
Pathologic Processes